Evgen Pharma

About:

Evgen Pharma is a clinical stage drug development company focused on the treatment of cancer and neurological conditions

Website: http://evgen.com/

Twitter/X: evgenpharma

Top Investors: Seneca Partners, The North West Fund, Acceleris Capital, Enterprise Ventures, Sarum Partners

Description:

Evgen Pharma is a clinical stage drug development company focused on the treatment of cancer and neurological conditions. Evgen’s pipeline is based on our proprietary Sulforadex® technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane. Many peer-reviewed scientific papers have identified the medical potential of sulforaphane in multiple indications. Our objective is to use our Sulforadex® technology to turn this scientific promise into commercially successful products.

Total Funding Amount:

$16.4M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Wilmslow, Cheshire, United Kingdom

Founded Date:

2007-01-01

Contact Email:

enquiries(AT)evgen.com

Founders:

Stephen Franklin

Number of Employees:

1-10

Last Funding Date:

2021-02-03

IPO Status:

Public

Industries:

© 2025 bioDAO.ai